KHC vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 22, 2026

KHC

58.1
AI Score
VS
KHC Wins

MRNA

49.9
AI Score

Investment Advisor Scores

KHC

58score
Recommendation
HOLD

MRNA

50score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric KHC MRNA Winner
Net Income -4.66B -2.82B MRNA
Operating Income -5.29B -3.07B MRNA
ROE -12.9% -32.6% KHC
ROA -6.4% -22.9% KHC
Total Assets 73.06B 12.34B KHC
Cash 2.42B 2.60B MRNA
Debt/Equity 0.38 0.07 MRNA
Current Ratio 1.06 3.29 MRNA
Free Cash Flow 1.66B -2.06B KHC

Relative Price Performance (Last 90 Days)

KHC 1M: -6.2% · 3M: +6.8% MRNA 1M: +25.8% · 3M: +199.3%

Current Technical Phase

KHC

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 39

RSI (14): 38.5 · Price: $24.00

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (47.8% over 20 days), RSI 72

RSI (14): 72.2 · Price: $182.56

Fundamentals Snapshot

Metric KHC MRNA
Market Cap
Forward P/E 11.5 -38.1
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% 0.0%
Gross Margin 0.3% -0.7%
Operating Margin 0.2% -5.6%
EPS -2.88 -7.98
Dividend Yield 0.07%

Frequently Asked Questions

Based on our detailed analysis, KHC is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.